BTS Quality Standards for Home Oxygen Use in Adults

Appendix 4

Protocol for Ambulatory Oxygen Therapy Assessment from the BTS Home Oxygen Guideline (2015)


Aims of assessment for each patient

- (1) To determine if there is desaturation on exercise, defined as a drop in SpO2 of \geq 4% to < 90%
- (2) To determine the most appropriate device and setting to correct exercise desaturation

Considerations

- This protocol is designed to be generic and can be adapted for any valid and repeatable walking test.
- A 6 Minute Walking Test (6MWT) should be performed over a 30m course (cones 29m apart), but it is recognised that due to a lack of space a modified 10m-6MWT (cones 9m apart) may be used as an alternative(1, 2). Incremental and Endurance Shuttle Walking Tests (ESWT) are performed over a 10m course (cones 9m apart). There is some evidence to show that endurance tests, such as the ESWT, may be more sensitive than standard tests (3, 4).
- Desaturation during baseline endurance shuttle walking test (ESWT) has been found to predict required flow rate (see annex 1). This is unlikely to predict as robustly when desaturations produced during other walking tests are used but may give some guidance.
- A practice walk test should be performed and without one the improvement in walking distance from air to oxygen is likely to be overestimated.
- Local policy and individual patient capabilities will affect the maximum number of tests performed in one appointment. Two appointments may be required to titrate oxygen fully.
- It is not possible to correct SpO2 in every patient to >90% using 6 litres per minute (lpm) oxygen
 or the maximum settings on other devices. In this situation discussion with patient and their
 consultant may help determine if a higher flow rate may be suitable. Portability and / or
 duration of use declines considerably above 6 lpm.
- Authors have described a dose response to oxygen i.e. for each increase in flow rate there is an increase in exercise performance (3). Those whose performance has not improved on oxygen should therefore be trialled on a higher flowrate / setting.
- Carrying the cylinder / device negates the effect of the oxygen but wheeling it does not (5). Therefore patients must have AOT flow rate / setting titrated while carrying / wheeling the oxygen device as they plan to use it in everyday life.
- Different oxygen devices weigh different amounts and oxygen conservers vary in sensitivity and functionality which result in devices responding differently to different patients (6). Patients must have the flow / setting titrated on the device that they are to be prescribed.

Equipment Required	Preparation
 Long, flat, corridor at least 32m long (12m for modified 6MWT) 2 cones 2 chairs (placed beyond each cone) Stopwatch/CD & CD player Ambulatory oxygen equipment (hired / supplied by oxygen provider) Nasal cannulae Pulse oximeter Modified BORG breathlessness scale Oxygen risk assessment Patient information leaflets 	 Explain the purpose of AO Outline the AO assessment process Gain informed consent for assessment Confirm indication for AO (including outdoor mobility) Complete risk assessment Ensure 20 mins rest before walking test (included in discussion time) Set up walking test circuit Read / play test instructions Ask if the patient has any questions Perform practice test Ensure further 20 mins rest before retest



Demonstrating a positive improvement with AOT

2 out of 3 of the markers below are required to show that the patient benefits from AOT.

- SpO2s ≥90% throughout
- \geq 10% increase in walking distance from baseline (7)
- Improvement in BORG of at least 1 point from baseline (8)

Follow-up

8 week review:

Check patient's concordance with the oxygen order (call the oxygen delivery company to determine their usage) and compare this with the patient's diary card when they attend. Discuss any discrepancies or issues highlighted.

Troubleshoot any device issues. Review device and oxygen order as required

Annual review:

Reassess using current prescription and adjust flow rate and device as required

Annex 1

Suggested AOT flow rates according to baseline ESWT desaturations (9):

Oxygen saturation range (%)	Suggested AOT flow rate (I/min)
86-89	3
80-85	4
74-79	5
73 or below	6

References:

- Beekman E, Mesters I, Gosselink R, Klaassen MPM, Hendriks EJM, Van Schayck OCP, De Bie RA. The first reference equations for the 6-minute walking distance over a 10 metre course. Thorax 2014. <u>http://thorax.bmj.com/content/early/2014/04/23/thoraxjnl-2014-205228</u>
- (2) Crapo RO, Casaburi R, Coates AL, et al (2002) American Thoracic Society Statement Guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine. 166 p 111 – 117. http:/ajrccm.atsjournals.org/cgi/content/full/166/1/111 [accessed 02/07/2007]
- (3) Davidson AC, Leach R, George RJD, Geddes DM. 1988. Supplemental oxygen and exercise ability in chronic obstructive airways disease. *Thorax*, 43: 965-971.
- (4) Ambulatory oxygen therapy assessment: a comparative study of incremental shuttle and 6minute walking tests A. Lewko, J. Marshall, R. Garrod Physiotherapy - December 2007 (Vol. 93, Issue 4, Pages 261-266, DOI: 10.1016/j.physio.2007.03.002).

- (5) Leggett RJE, Flenley DC. 1977. Portable oxygen and exercise tolerance in patients with chronic hypoxic cor pulmonale. British Medical Journal, ii: 84-86.
- (6) Bliss PL, McCoy RW, Adams AB. 1999. A bench Study Comparison of Demand Oxygen Delivery Systems and Continuous Flow Oxygen. Respiratory Care, 44 (8): 925-931.
- (7) Dyer F, Callaghan J, Cheema K, Bott J. Ambulatory oxygen improves the effectiveness of pulmonary rehabilitation in selected patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease. 2012. 9;83-91
- (8) Ries AL. Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. Journal of Chronic Obstructive Pulmonary Disease 2005; 2 (1)105-110.
- (9) Cornish L, Dyer F, Cheema K, Bott J. Is it possible to predict ambulatory oxygen (AO) requirements? Thorax 2013;**68**:Suppl 3 A92 doi:10.1136/thoraxjnl-2013-204457.188